The SMC (Scottish Medicines Consortium) say that they do not consider ocrelizumab to be cost effective for the NHS in Scotland as a treatment for relapsing remitting MS in comparison to the existing disease modifying drugs. The SMC state that Roche, the manufacturer of the drug, did not present a sufficiently robust economic assessment of the drug's use for it to be accepted.
We anticipate that Roche will continue to work with the SMC with the aim of changing this initial decision.
We also understand that the SMC submission for ocrelizumab for primary progressive MS has been withdrawn.
We are very concerned at the continuing delay for people with MS to access ocrelizumab in Scotland. For people with relapsing MS, it expands the range of MS treatments by offering a different dosing schedule, a different mode of action, minimal monitoring and a low risk of side effects compared to existing disease modifying drugs. In primary progressive MS, ocrelizumab is the first treatment which has been shown to slow down progression. We will continue to make the strongest possible case for NHS Scotland approval of ocrelizumab for both relapsing and primary progressive MS.
Jo Sopala, Director of Development
In June, NICE approved ocrelizumab for relapsing remitting MS but rejected it for primary progressive MS in England and Wales.
Read more about ocrelizumab.